B. Nightengale

The economic burden of non-influenza-related viral respiratory tract infection in the United States.

A. Fendrick, A. Monto, B. Nightengale, 2003, Archives of internal medicine.

Cost-Effectiveness of Thallium-201 versus Technetium-99m-Sestamibi in the Detection of Coronary Artery Disease

B. Nightengale, 1995 .

High-risk patients with hypertension: Are we doing enough?

B. Nightengale, H. Dastani, J. Sobolski, 2008, Journal of the American Society of Hypertension : JASH.

Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomycosis.

B. Nightengale, M. Sarnes, C. Russo, 2005, Managed care interface.

Relationship of Blood Pressure Control to Adherence With Antihypertensive Monotherapy in 13 Managed Care Organizations

B. Nightengale, Feride Frech-Tamas, T. Bramley, 2006, Journal of managed care pharmacy : JMCP.

Economic Impact of Cost-Containment Strategies in Third Party Programmes in the US (Part I )

B. Nightengale, C. Pedersen, R. Schulz, 1993, PharmacoEconomics.

Practice Efficiency and Economics: The Case for Rapid Recovery Sedation Agents for Colonoscopy in a Screening Population

B. Nightengale, K. Meyer, J. Vargo, 2007, Journal of clinical gastroenterology.

Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms.

M. Jhaveri, B. Nightengale, M. Goodman, 2008, American health & drug benefits.

Cost-Effectiveness of Thallium-201 versus Technetium-99m-Sestamibi in the Detection of Coronary Artery Disease

B. Nightengale, 1995 .